secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001193125-22-148067
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience Q1 2022: FYARRO sales $2.3M; net loss $13.9M; first patient dosed in PRECISION 1 trial
--------------------------------------------------------------------------------

- Net product sales of FYARRO were $2.3M for partial first quarter since launch in Feb 2022.
- Net loss for Q1 2022 was $13.9M vs $5.5M in Q1 2021; operating expenses $16.1M vs $4.2M.
- Cash and equivalents $129.8M as of Mar 31, 2022, expected to fund operations into 2024.
- First patient dosed in PRECISION 1 Phase 2 tumor-agnostic trial for TSC1/TSC2 altered tumors; initial data expected H1 2023.
- Permanent J-code (J9331) for FYARRO granted, effective Jul 1, 2022; partnerships with Foundation Medicine and Tempus for trial enrollment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522148067/0001193125-22-148067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522148067/d326757d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-148067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer